CCL22 and neoplasm: Also, other fucoidans can downregulate some cytokines and chemokines (e.g., M2-type chemokine CCL22) to inhibit tumor cell migration and lymphocytes recruitment via NF-κB-dependent transcription, which may be a novel and promising mechanism for tumor immunotherapy [46].